Electronic Supplementary Material (ESI) for RSC Advances. This journal is © The Royal Society of Chemistry 2014

Copies of ¹H and ¹³C Spectra



Fig. 1: ¹H NMR spectra of compound **4a** (CDCl₃, 400 MHz)



Fig. 2: ¹H-¹H COSY spectra of compound **4a** (CDCl₃, 400 MHz)



Fig. 3: 1D-NOE spectra of compound 4a (CDCl₃, 400 MHz)



Fig. 4: ¹³C NMR spectra of compound **4a** (CDCl₃, 100 MHz)

	SAMPLE	INFORMATI	O N	
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	ILS/ARJ/5/1 Unknown 27 1 10.00 ul 30.0 Minutes	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.:	240214 CFZ CFZ_PRO 280.0nm PDA 280.0 nm	
Date Acquired: Date Processed:	2/24/2014 12:13:33 PM IST 2/24/2014 12:49:24 PM IST			



Fig. 5: HPLC of compound 4a



Fig. 6: Mass of compound 4a



Fig. 7: ¹H NMR spectra of compound **4b** (CDCl₃, 400 MHz)



Fig. 8: ¹³C NMR spectra of compound **4b** (CDCl₃, 100 MHz)

To describe a second			Seq Line	:		27
Injection Date	:	Wed, 19. Feb. 2014	Location	:	Vial	15
Sample Name	:	ILS-ARJ-5-2	Inj. No.	:		1
Acq Operator	:	RADHA	Inj. Vol.	:	5	11
Acq. Method	:	D:\chem32\1\DATA\180214-API	2014-02-18		1-22\APT	->
Analysis Method	:	D:\CHEM32_002\1\METHODS\API	MKT.M			
Method Info	:	Column : X-Terra RP18 250*	4.6mm,5µm			
		Mobile phase: A)0.1%TFA in W	Water B) ACN	(gra	adient)	
		T/B%:0/20,3/20,12/95,23/95,2	25/20,30/20	. 3		
		Flow:1.0 ml/min, Diluent: MH	EOH			



Signal 1: DAD1 C, Sig=235,5 Ref=off

Pea	ak	RT	Ι	Area	I	Area	6
#	ł	[min]	1		1		1
!			- -				
1	11	11.09	4	5.25	541	0.3	3701
I	21	12.06	11	6.27	71	0.4	421
I	31	13.51	31	23.07	11	1.6	5251
I	41	13.92	81	6.97	91	0.4	92
1	51	15.22	01	1350.56	21	95.1	17
1	61	15.36	01	21.91	01	1.5	43
I	71	16.23	21	5.84	61	0.4	12

M / . Iur

Fig. 9: HPLC of compound 4b



Fig. 10: Mass of compound 4b



Fig. 11: ¹H NMR spectra of compound **4c** (CDCl₃, 400 MHz)



Fig. 12: ¹³C NMR spectra of compound **4c** (CDCl₃, 100 MHz)

			Seq Line	:	0
Injection Date	:	Wed, 19. Mar. 2014	Location	:	Vial 24
Sample Name	:	ILS/ARJ/5/15	Inj. No.	:	0
Acq Operator	:	RADHA	Inj. Vol.	:	0 µl
Acq. Method	:	D:\CHEM32_002\1\METHODS\C-18	A20B80.M		
Analysis Method	:	D:\CHEM32_002\1\METHODS\C-18-	-A70B30G.M		
Method Info	:	Column :Symmetry C-18 75*4.6r	ռտ, 3.5µm		
		Mobile phase: A) 0.1% TFA in	water,B) AC	:N	(gradient)
		T/B%:0/20,1/20,4/98,10/98,10	.5/20,12/20.		
		FLOW:1.0ml/min Dil: ACN:Water	(80:20)		



Signal 1: DAD1, Sig=240.00, 1.00 Ref=off, EXT

Peak	RT	Area	Area %				
#	[min]	I	1	(Donk L		-	_
-	-	-		(Feak)	RT	Area	Area %
1	3.629	25.2021	0.416	1 # 1	[min] [1	i
2	3.873	23.804	0.393				!
3	4.019	4.807	0.0791	1 121	5.659!	5987.527	91.288
4	4.119	71.525	1.180	13	5.8461	45.0371	0.743
1 51	4.192	25.8391	0.426	14	8.470	167.897!	2.770
6	4.361	41.430	0.684	15!	8.886!	4.301	0.071
7	4.539	12.341	0.2041				
8	4.825	29.262	0.483				
91:	4.927	6.569	0.108				
10	5.161	24.979	0.354				
11	5.399	48.567	0.801				

Fig. 13: HPLC of compound 4c



Fig. 14: Mass of compound 4c



Fig. 15: ¹H NMR spectra of compound **4d** (CDCl₃, 400 MHz)



Fig. 16: ¹³C NMR spectra of compound **4d** (CDCl₃, 100 MHz)

			Seq I	ine	:	0
Injection Date	:	Wed, 19. Mar. 2014	Locat	ion	:	Vial 23
Sample Name	:	ILS/ARJ/5/14	Inj.	No.	:	0
Acq Operator	:	RADHA	Inj.	Vol.	I	0 µl
Acq. Method	:	D:\CHEM32_002\1\METHODS\C-18	A20B80).М		
Analysis Method	:	D:\CHEM32_002\1\METHODS\C-18-	-A70B30	G.M		
Method Info	:	Column :Symmetry C-18 75*4.6m	nm, 3.5	ուղմ		
		Mobile phase: A) 0.1% TFA in	water,	B) ACM	1 (gradient)
		T/B%:0/20,1/20,4/98,10/98,10.	5/20,1	2/20.		
		FLOW:1.0ml/min Dil: ACN:Water	(80:20))		



Signal 1: DAD1, Sig=315.00, 1.00 Ref=off, EXT

Pea	ak	RT	I	Area	Ι	Area	8	
1 0	Τ.	[min]	I		Ι		1	
			- -					
1	11	3.78	31	14.60	180	0.1	341	
1	21	3.98	1	157.93	121	1.4	150	
1	3.[4.32	61	1.60	521	0.0)15	
1	4 E	4.44	0]	10.34	16	0.0	951	
1	51	4.58	7	7.5	191	0.0	0691	
1	61	4.97	21	10664.79	991	97.9	961	
1	71	5.44	7	4.8	731	0.0)451	
1	81	5.79	4	20.33	341	0.1	L87	
1	91	6.14	01	2.18	391	0.0	201	l
1 1	101	6.28	71	2.50	54 I	0.0	24	
								-

N 19103114

Fig. 17: HPLC of compound 4d



Fig. 18: Mass of compound 4d



Fig. 19: ¹H NMR spectra of compound **4e** (CDCl₃, 400 MHz)



Fig. 20: ¹³C NMR spectra of compound **4e** (CDCl₃, 100 MHz)

	SAMPLE	INFORMATIC	O N	
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time: Date Acquired: Date Processed:	ILS/ARJ/5/11 Unknown 36 1 5.00 ul 30.0 Minutes 2/22/2014 12:44:32 AM IST 2/24/2014 11:59:50 AM IST	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.:	210214_1 CFZ CFZ_PRO 290.0nm PDA 290.0 nm	



Fig. 21: HPLC of compound 4e



Fig. 22: Mass of compound 4e



Fig. 23: ¹H NMR spectra of compound **4f** (CDCl₃, 400 MHz)



Fig. 24: D₂O exchange spectra of compound **4f** (CDCl₃, 400 MHz)



Fig. 25: ¹³C NMR spectra of compound **4f** (DMSO- d_6 , 100 MHz)

Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	ILS/ARJ/5/10 Unknown 35 1 5.00 ul 30.0 Minutes	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.:	240214 CFZ CFZ_PRO 280.0nm PDA 280.0 nm	
Date Acquired: Date Processed:	2/24/2014 11:37:36 AM IST 2/24/2014 12:51:16 PM IST			



Fig. 26: HPLC of compound 4f



Fig. 27: Mass of compound 4f



Fig. 28: ¹H NMR spectra of compound **4g** (CDCl₃, 400 MHz)



Fig. 29: ¹³C NMR spectra of compound **4g** (CDCl₃, 100 MHz)

SAMPLE	

Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	ILS/ARJ/5/3 Unknown 28 1 5.00 ul 30.0 Minutes	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.;	210214_1 CFZ CFZ_PRO 275.0nm PDA 275.0 nm	
Date Acquired: Date Processed:	2/21/2014 7:58:58 PM IST 2/24/2014 11:38:42 AM IST			



Fig. 30: HPLC of compound 4g



Fig. 31: Mass of compound 4g



Fig. 32: ¹H NMR spectra of compound **4h** (CDCl₃, 400 MHz)



Fig. 33: ¹³C NMR spectra of compound **4h** (CDCl₃, 100 MHz)

	SAMPLE	INFORMATIC	ΟN			
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	ILS/ARJ/5/9 Unknown 34 5.00 ul 30.0 Minutes	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.:	210214_1 CFZ CFZ_PRO 280.0nm PDA 280.0 nm			
Date Acquired: Date Processed:	2/21/2014 11:33:12 PM IST 2/24/2014 11:52:31 AM IST					
Column: X TERRA RR 40 05014 0						



Fig. 34: HPLC of compound 4h



Fig. 35: Mass of compound 4h



Fig. 36: ¹H NMR spectra of compound **4i** (CDCl₃, 400 MHz)


Fig. 37: ¹³C NMR spectra of compound **4i** (CDCl₃, 100 MHz)

Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	ILS/ARJ/5/7 Unknown 32 1 5.00 ul 30.0 Minutes	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.:	210214_1 CFZ CFZ_PRO 280.0nm PDA 280.0 nm	
Date Acquired: Date Processed:	2/21/2014 10:21:46 PM IST 2/24/2014 11:48:10 AM IST			



Fig. 38: HPLC of compound 4i



Fig. 39: Mass of compound 4i



Fig. 40: ¹H NMR spectra of compound **4j** (CDCl₃, 400 MHz)



Fig. 41: ¹³C NMR spectra of compound **4j** (CDCl₃, 100 MHz)

			Seq	Line	:	0
Injection Date	:	Wed, 19. Mar. 2014	Loca	tion	:	Vial 21
Sample Name	:	ILS/ARJ/5/12	Inj.	No.	:	0
Acq Operator	:	RADHA	Inj.	Vol.	:	0 µl
Acq. Method	:	D:\CHEM32_002\1\METHODS\C-18	A20B8	0.M		
Analysis Method	:	D:\CHEM32_002\1\METHODS\C-18-	-A70B3	0G.M		
Method Info	:	Column :Symmetry C-18 75*4.6m	nm, 3.	5µm		
		Mobile phase: A) 0.1% TFA in	water	,B) ACI	N	(gradient)
		T/B%:0/20,1/20,4/98,10/98,10.	5/20,	12/20.		
		FLOW:1.0ml/min Dil: ACN:Water	(80:2	0)		



Signal 1: DAD1, Sig=285.00, 1.00 Ref=off, EXT

P	eakl	RT	Area	Area %
l	# I	[min]	I I	I
L	1	4.028	2.023	0.1661
L	21	4.451	17.173	1.408;
L	31	4.621	0.928	0.076
L	41	5.060	15.705	1.288
	51.	5.109	27.077	2.220
1	61	5.483	1.724	0.141
L	71	5.590	2.553	0.2091
L	81	5.837	17.519	1.436
I	91	5.947	20.3221	1.666
I	101	6.161	0.857	0.070
I	11	6.738	1113.814	91.319

11/

Fig. 42: HPLC of compound 4j



Fig. 43: Mass of compound 4j



Fig. 44: ¹H NMR spectra of compound **4k** (CDCl₃, 400 MHz)



Fig. 45: ¹³C NMR spectra of compound **4k** (CDCl₃, 100 MHz)

Injection Date	:	Wed, 19. Mar. 2014	Location	:	Vial 22	2
Sample Name	:	ILS/ARJ/5/13	Inj. No.	:	(0
Acq Operator	:	RADHA	Inj. Vol.	: •	0 μ	1
Acq. Method	:	D:\CHEM32_002\1\METHODS\C-18	A20B80.M			
Analysis Method	:	D:\CHEM32_002\1\METHODS\C-18-	A70B30G.M			
Method Info	:	Column :Symmetry C-18 75*4.6m	տ, 3.5µm			
		Mobile phase: A) 0.1% TFA in	water, B) ACM	۹ (g	radient)	
		T/B%:0/20,1/20,4/98,10/98,10.	5/20,12/20.			
		FLOW:1.0ml/min Dil: ACN:Water	(80:20)			



Signal 1: DAD1, Sig=285.00, 1.00 Ref=off, EXT

F	eak!	RT	Area	Area 🖇				
\cdot	# 1	[min]	1	1	Peak	PT I	D == = = = = = =	
- ا		-			1 # 1	[min]	Area !	Area %
L	11	4.123	3.570	0.075	1 1	[mrn] [1	. [
L	21	4.732	19.446	0.406	1 121	6 9601		
I.	31	4.932	7.481	0.156	1 13/	7 2701	3595.715	92.094
I.	41	5.091	5.208	0.109	1 141	7.276	1./90	0.0351
L	51	5.476	66.204	1.383		/.800	63.376!	1.3241
I.	61	5.6431	32.734	0.684				
Т	71	5.806	13.061	0.273				
1	81	6.041[46.150	0.964				
L	91	6.253	5.9791	0.125				
1	101	6.524	25.533	0.533				
1	11	6.733	11.030	0.230				

Fig. 46: HPLC of compound 4k



Fig. 47: Mass of compound 4k



Fig. 48: ¹H NMR spectra of compound **4I** (CDCl₃, 400 MHz)



Fig. 49: ¹³C NMR spectra of compound **4l** (CDCl₃, 100 MHz)





Signal 1: DAD1, Sig=240.00, 1.00 Ref=off, EXT

] P6	eak	RT	1	Area	ł	Area	8	I
14	+ 1 .	[min]	1					l
			-1-					I
	11	6.16	71	6501.81	151	92.2	96	
[21	6.33	5	9.07	781	0.1	.28	l
1	31	6.46	4	193.77	731	2.7	27	l
I	4	6.68	4	29.83	361	0.4	20	
L	51	6.80	91	178.95	52 I	2.5	518	1
1	6	7.16	4	17.48	391	0.2	246	i
1	71 -	7.32	31	6.00	551	0.0	85	l
	8	7.57	91	7.62	27	0.1	07	i
1	91	7.73	0	40.47	71	0.5	570	L
i	10	7.83	61	2.20	9	0.0)31	L
Ι.	111	8.05	21	66.10	67	0.9	931	L

Fig. 50: HPLC of compound 41



Fig. 51: Mass of compound 41



Fig. 52: ¹H NMR spectra of compound **4m** (CDCl₃, 400 MHz)



Fig. 53: ¹³C NMR spectra of compound **4m** (CDCl₃, 100 MHz)

	SAMPLE	INFORMATIC	O N 0
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	ILS/ARJ/5/4 Unknown 29 1 5.00 ul 30.0 Minutes	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.:	210214_1 CFZ CFZ_PRO PDA Max Plot 190.0 - 800.0 @2 PDA MaxPlot (190.0 nm to 800.0
Date Acquired: Date Processed:	2/21/2014 8:34:40 PM IST 2/24/2014 11:42:25 AM IST		



Fig. 54: HPLC of compound 4m



Fig. 55: Mass of compound 4m



Fig. 56: ¹H NMR spectra of compound **4n** (CDCl₃, 400 MHz)



Fig. 57: ¹³C NMR spectra of compound **4n** (CDCl₃, 100 MHz)

Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	ILS/ARJ/5/5 Unknown 30 1 5.00 ul 30.0 Minutes	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.:	210214_1 CFZ CFZ_PRO 285.0nm PDA 285.0 nm
Date Acquired: Date Processed:	2/21/2014 9:10:24 PM IST 2/24/2014 11:43:53 AM IST		



Fig. 58: HPLC of compound 4n



Fig. 59: Mass of compound 4n



Fig. 60: ¹H NMR spectra of compound **40** (CDCl₃, 400 MHz)



Fig. 61: ¹³C NMR spectra of compound **40** (CDCl₃, 100 MHz)

		<u>INTORMATIO</u>		
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	ILS/ARJ/5/6 Unknown 31 1 5.00 ul 30.0 Minutes	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.:	210214_1 CFZ CFZ_PRO 285.0nm PDA 285.0 nm	
Date Acquired: Date Processed:	2/21/2014 9:46:05 PM IST 2/24/2014 11:45:55 AM IST			



Fig. 62: HPLC of compound 40



Fig. 63: Mass of compound 40



Fig. 64: ¹H NMR spectra of compound **4p** (CDCl₃, 400 MHz)



Fig. 65: ¹³C NMR spectra of compound **4p** (CDCl₃, 100 MHz)

	SAMPLE	INFORMATIO	ON	
Sample Name: Sample Type: Vial: Injection #: Injection Volume: Run Time:	ILS/ARJ/5/8 Unknown 33 1 5.00 ul 30.0 Minutes	Sample Set Name: Acq. Method Set: Processing Method: Channel Name: Proc. Chnl. Descr.:	210214_1 CFZ CFZ_PRO 280.0nm PDA 280.0 nm	
Date Acquired: Date Processed:	2/21/2014 10:57:31 PM IST 2/24/2014 11:49:42 AM IST	_		
Column V TEDDA DD	10.000			



Fig. 66: HPLC of compound 4p



Fig. 67: Mass of compound **4p**



Fig. 68: ¹H NMR spectra of compound **4q** (CDCl₃, 400 MHz)



Fig. 69: ¹³C NMR spectra of compound **4q** (CDCl₃, 100 MHz)

Injection Date		No. 10	Seq Line	:		0
injection bate	:	Mon, 10. Feb. 2014	Location	:	Vial	1
Sample Name	:	ILS-BPS-3-171	Ini No			-
Acq Operator	:	RADHA	Inj. NO.	•		0
Acq. Method			inj. vol.	:	15	μl
and the choo	•	D: (CHEM32_002(1(METHODS)C-18	A80B20GS.M			
Analysis Method	:	D:\CHEM32 002\1\METHODS\C-18	A80B20GS_M			
Method Info	:	Column : Symmetry C-18 75*4	.6mm, 3.5um			
		Mobile phase: A) 0.1% HCOOH	in Water B	7.011		
		T/B%:0/20.0.5/20 4/98 10/08	In water , B)	ACN		
		Eleve 1.0 -1/20, 1/30, 10/38,	10.5/20,12/20)		
		riow: 1.0 mi/min, Diluent: Ad	CN:Water(80:2	0)		



Fig. 70: HPLC of compound 4q



Fig. 71: Mass of compound 4q



Fig. 72: ¹H NMR spectra of compound **5** (CDCl₃, 400 MHz)


Fig. 73: ¹³C NMR spectra of compound **5** (CDCl₃, 100 MHz)



Fig. 74: ¹H NMR spectra of compound **6** (CDCl₃, 400 MHz)



Fig. 75: ¹³C NMR spectra of compound **6** (CDCl₃, 100 MHz)

Inj Date	:	Mon, 14. Apr. 2014 Acq Operator: SHASHIDHAR				
Sample Name	:	ILS/ARJ/5/26 Vial 5				
A.R Number	:	CM14D010 -> Inj. Vol. : 10µL				
Acq. Method	:	D:\CHEM32_002\1\METHODS\C-18 A80B20.M				
Analysis Method	:	D:\CHEM32_002\1\METHODS\C-18 A80B20.M				
Method Info	:	Column : Symmetry C-18 75*4.6mm3.5µm				
		Mobile phase: A) 0.1% TFA in water , B) ACN				
		T/B% : 0/20,1/20,6/98,10/98,12/20,15/20.				
1		Flow: 1.0 ml/min Diluent: ACN:Water(80:20)				



Signal 1: DAD1, Sig=250.00, 1.00 Ref=off, EXT

Peak	I RT	1	Area	Area %
4	[min	1 1		1
	L			
1	I 5.	308	47.263	2.778
2	5.	516	1.210	0.071
3	5.	898	21.233	1.248
4	6.	0841	1601.773	94.132
5	6.	350[3.514]	0.207
Ι.6	I 6.	746[7.196	0.423
7	1. 7.	158	16.680	0.980
1 8	1 7.	668	2.752	0.162

Fig. 76: HPLC of compound 6



Fig. 77: Mass of compound 6